Notice of Intent to Award - Blanket Purchase Agreement (BPA) for Compounded Pharmaceuticals via 503B Compounding Pharmacies

Notice of Intent to Award –Blanket Purchase Agreement for Compounded Pharmaceuticals via 503B Compounding Pharmacies In accordance with FAR 13.303-2(c)(2), the Navajo Area Indian Health Service, Gallup Service Unit in Gallup, New Mexico, intends to award a Blanket Purchase Agreement (BPA) to Fagron Compounding Services LLC for compounded pharmaceuticals from a FDA-designated 503B facility on an as-needed basis.

Items include Phenylephrine 100mcg/ml, Succinylcholine 20mg/10ml, LET 5ml syringe, Oxytoxin 30 units in 500ml (sterile to sterile and API), Epinephrine 8mg per 250ml bag (or other strengths/volumes of the same medications in IV bags as available and required on an as-needed basis). Products must be sterilely compounded in an FDA approved facility with a beyond use date of at least 30 days from manufacture. The anticipated period of performance is 4/1/2024-3/31/2025.

The applicable North American Industry Classification System (NAICS) code assigned to this procurement is 325412- Pharmaceutical Preparation Manufacturing with a small business size standard of 1,300 employees. No further awards will be made unless the need for Gallup Indian Medical Center changes. The prospective BPA as identified in this notice is sufficient at this time.

Any other sources that believe they are capable of fulfilling the government requirements as described are encouraged to submit their capability statement, price lists, and catalogs to the Point of Contact listed below via email only and no later than 3/18/2024 at 10:00 AM (MDT). In the event additional BPAs are deemed to be in the best interest of the government, capable vendors may be contacted. This notice of intent is not a request for quotations and a solicitation will not be issued in conjunction with the notice of intent.